Timothy Kuzel MD FACP
Cutaneous Lymphoma, Genitourinary Oncology, Hematologic Oncology, Melanoma
Clinical Professor of Medicine Northwestern University Distinguished Physician, St George corp Associate Director Clinical Research Network, Robert H Lurie Comprehensive Cancer Center Northwestern University Oncology Service Line Lead, South Region
Join to View Full Profile
15300 West AveRobert H Lurie Comp Ca CtrOrland Park, IL 60462
Phone+1 708-226-2513
Fax+1 312-942-3192
Dr. Kuzel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a Clinical Professor of Medicine at Northwestern University, and Associate Director for Clinical Research Network for the Robert H. Lurie Comprehensive Cancer Center of NU, and the Oncology Service Line director of the south region for the Northwestern Medicine Health system. Prior to this, I was a Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University from June 2016 to Nov 2023. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. My career has been focused on the execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies. I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global clinical trials.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
University of Michigan Medical SchoolClass of 1984
University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981- University of MichiganB.S., Biomedical Sciences, 1981
Certifications & Licensure
IL State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
- America's Top Doctors Castle Connolly, 2008-2017
- America's Top Doctors for Cancer Castle Connolly, 2007-2017
Clinical Trials
- Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1991 Oct 01
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 May 20
- Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1998 May 01
Publications & Presentations
PubMed
- IL-15 Complexes Combined with PD-1 Blockade Affect Immune Cell Distribution, Localization, and Immune Signatures in Regressing Versus Non-Regressing Metastatic Breast ...Josef W Goldufsky, Anjelica F Reyes, Allie A Heller, Malia E Leifheit, Maram N Albalawi
International Journal of Molecular Sciences. 2025-11-27 - 4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response.Jihae Ahn, Ping Xie, Siqi Chen, Guilan Shi, Jie Fan
The Journal of Clinical Investigation. 2025-06-02 - 9 citationsEfficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2025-04-01
Journal Articles
- Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor SuppressionTimothy M Kuzel, Bin Zhang, The Journal of Immunology
- The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to ActionAgne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
- The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature reviewSchwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
Books/Book Chapters
Abstracts/Posters
- A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs LymphomaTimothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of use of Phosphodiesterase Type 5 Inhibitors (PDE5-I) after Radical Prostatectomy (RP) on Biochemical Recurrence-free (BCRF) and Overall Survival (OS): A Retro...Arden B. Roston, Irene B. Helenowski, William Catalona, Robin Leikin, Michael Gurley, Luke Trapp, Borko Jovanovic, Timothy M. Kuzel, J Clin Oncol; Proc of GU ASCO, 1/1/2017
- Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell...Sumanta Pal, Robert J Motzer, Mayer Fishman, Raymond McDermott, Jose Passos Coelho, Evgeniy Kopyltsov, Xavier Garcia del Muro Solans, Jesús Garcia Donas, Ramazan Yildi..., J Clin Oncol; Proc of GU ASCO, 1/1/2017
Lectures
- Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...London, United Kingdom - 1/13/2017
- Immunotherapy of Cancer1/1/2012
- A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma.1/1/2009
Other
- The use of Gemcitabine in metastatic urothelial transitional cell cancerKuzel TM and Stadler WM, Lilly Monograph
1/1/1996 - Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2.Kuzel TM, Doody's Health Sciences Book Review Annual
1/1/1993 - Interferons: Basic Principles and Clinical Applications.Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
1/1/1993
Press Mentions
Investigating New Treatments for Rare Skin LymphomasJanuary 17th, 2025- Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic MutationsSeptember 6th, 2024
Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
